КРИСТАЛЛИЧЕСКИЕ ФОРМЫ ИНГИБИТОРА KRas G12C

EA054054B1Active Publication Date: 2026-07-17MIRATI THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
EA · EA
Patent Type
Patents
Current Assignee / Owner
MIRATI THERAPEUTICS INC
Filing Date
2021-09-10
Publication Date
2026-07-17

Smart Images

  • Figure 00000046_0000
    Figure 00000046_0000
  • Figure 00000046_0001
    Figure 00000046_0001
  • Figure 00000047_0000
    Figure 00000047_0000
Patent Text Reader

Abstract

The present invention relates to crystalline forms of a KRas G12C inhibitor and salt thereof. In particular, the present invention relates to crystalline forms of the KRas GT2C inhibitor 2-[(2S)- 4-[7-(8-chloro-l-naphthyI)-2-[[(2S)-l-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H- pyrido[3,4-d]pyrimidin-4-yI]-l-(2-fluoroprop-2-enoyi)piperazin-2-yl]acetonitrile, pharmaceutical compositions comprising the crystalline forms, processes for preparing the crystalline forms and methods of use thereof.
Need to check novelty before this filing date? Find Prior Art